Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long Term Immune Response Produced by the SputnikV Vaccine

18 Oct 2021

Abstract excerpt

SputnikV is a vaccine against SARS-CoV-2 developed by the Gamaleya National Research Centre for Epidemiology and Microbiology. The vaccine has been shown to induce both humoral and cellular immune responses, yet the mechanisms remain largely unknown. Forty SputnikV vaccinated individuals were included in this study which aimed to demonstrate the location of immunogenic domains of the SARS-CoV-2 S protein using an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34681885
DOI: 10.3390/ijms222011211

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 14 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Long Term Immune Response Produced by the SputnikV VaccinePMID 34681885Read ↗

Memory B Cells Induced by Sputnik V Vaccination Produce SARS-CoV-2 Neutralizing Antibodies Upon Ex Vivo RestimulationSemantic proximity Read ↗

Evaluation of the Gam-COVID-Vac and Vaccine-Induced Neutralizing Response Against SARS-CoV-2 Lineage P.1 (Manaus) Variant in an Argentinean CohortSemantic proximity Read ↗

Antibody- and T cell-dependent responses elicited by a SARS-CoV-2 adenoviral-based vaccine in a socially vulnerable cohort of elderly individualsSemantic proximity Read ↗

Immunogenicity and safety of inactivated SARS-CoV-2 vaccine (CoronaVac) using two-dose primary protocol in children and adolescents (Immunita-002, Brazil): A phase IV six-month follow upSemantic proximity Read ↗

Mucosal and systemic responses to SARS-CoV-2 vaccination in infection naïve and experienced individualsSemantic proximity Read ↗

Vaccine Approaches for Pandemic COVID-19Semantic proximity Read ↗

A novel approach to designing viral precision vaccines applied to SARS-CoV-2Semantic proximity Read ↗

Sputnik V-induced Antibodies against SARS-CoV-2 Variants during the Dissemination of the Gamma Variant in VenezuelaSemantic proximity Read ↗

Design of novel multi-epitope vaccines against severe acute respiratory syndrome validated through multistage molecular interaction and dynamicsSemantic proximity Read ↗

Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in miceSemantic proximity Read ↗

Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.